Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 juil. 2026 09h00 HE | Source: Nuvectis Pharma, Inc.

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program in...
23 juil. 2026 07h30 HE | Source: Nuvectis Pharma, Inc.

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program in...
29 juin 2026 22h30 HE | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the...
29 juin 2026 16h01 HE | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment...
22 juin 2026 07h30 HE | Source: Nuvectis Pharma, Inc.

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor...
14 mai 2026 07h30 HE | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
05 mai 2026 07h30 HE | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights

NXP900 Phase 1b clinical program continues to enroll patients at select sites in the USNXP900 preclinical presentations at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting”...
31 mars 2026 08h00 HE | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
11 févr. 2026 07h30 HE | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
17 déc. 2025 07h00 HE | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the...

Page suivante